Staar Surgical Company
Research Staar Surgical Company (STAA) on Bullrun: market cap USD 1.16B, P/E 348.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSTAA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Market capUSD 1.16B
- P/E348.0
- Financial periodFY2026
- RevenueUSD 239.44M
- Revenue growth0.0%
- Net income-USD 80.45M
- Free cash flow-USD 40.05M
- Gross margin76.2%
Valuation Snapshot
latest market cap is USD 1.16B; P/E is 348.0.
Peer valuation comparison
Latest P/E is 348.05x versus a Healthcare sector median of 24.46x (1322.9% above).
Latest P/E is 348.05x versus a United States median of 24.87x (1299.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 239.44M | -USD 80.45M | -USD 40.05M | 76.2% | -1.62 | USD 153.15M | USD 37.29M | USD 344.18M |
| FY2025 | USD 239.44M | -USD 80.45M | -USD 40.05M | 76.2% | -1.63 | USD 153.15M | USD 38.35M | USD 344.18M |
| FY2024 | USD 313.90M | -USD 20.21M | -USD 7.67M | 76.3% | -0.41 | USD 144.16M | USD 38.74M | USD 397.34M |
| FY2023 | USD 322.42M | USD 21.35M | -USD 3.59M | 78.4% | 0.43 | USD 183.04M | USD 35.83M | USD 385.95M |
| FY2022 | USD 239.44M | USD 39.67M | USD 17.61M | 93.3% | 0.8 | USD 86.48M | USD 31.05M | USD 336.11M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.16B | 348.0 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.14B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.20B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.52B | 80.0 | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.34B | 63.0 | n/a | n/a |
| 2021 | 2021-12-31 | USD 4.36B | 182.6 | n/a | n/a |
About Staar Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Staar Surgical Company's market cap?
Staar Surgical Company's market capitalization is USD 1.16B.
What is Staar Surgical Company's P/E ratio?
Staar Surgical Company's price-to-earnings (P/E) ratio is 348.0.
What does Staar Surgical Company do?
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.